BTIG bullish on Delcath as timeline for cancer product approval appears steady

Delcath Systems

25/03/2022 17:34

** Medical device maker Delcath Systems Inc  DCTH.O  appears
to be on track with the timeline on resubmission of marketing
application for its cancer drug/device combination product
candidate, brokerage BTIG says 
    ** DCTH says it continues to target a mid-2022 resubmission
for Hepzato, a combination drug and device product for treating
a type of eye cancer  urn:newsml:reuters.com:*:nGNX3mgsM0
    ** Co also expects a pre-submission meeting with the U.S.
FDA in coming weeks 
    ** No surprises are anticipated as the meeting is expected
to be a forum for DCTH to confirm the data collected from its
clinical trial is adequate for review and to receive feedback on
how best to compile the data into a filing - brokerage
    ** 2H22 looks to be a catalyst-rich period for DCTH, BTIG
says; brokerage reaffirms "buy" rating on stock
    ** Up to Thursday's close, DCTH down ~18.5% YTD


 (Reporting by Manojna Maddipatla in Bengaluru)
 ((manojna.kalyani@thomsonreuters.com; +91  8061822700;))